Pseudomyxoma peritonei surgery: Difference between revisions
Jump to navigation
Jump to search
Nima Nasiri (talk | contribs) No edit summary |
Nima Nasiri (talk | contribs) |
||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{Nnasiri}}{{PSD}} | {{CMG}}{{AE}}{{Nnasiri}}{{PSD}} | ||
==Overview== | ==Overview== | ||
Pseudomyxoma peritonei is rare clinical syndrome characterized by the accumulation of ascites mucins in peritoneum, mainly arises from the appendix. The mainstay of therapy in patients with pseudomyxoma peritonei is cytoreductive surgery combined with intraperitoneal chemo infusion. | |||
==Surgery== | ==Surgery== | ||
*Surgery is the mainstay of treatment for pseudomyxoma peritonei. The feasibility of surgery depends on the stage of pseudomyxoma peritonei at diagnosis. | *Surgery is the mainstay of treatment for pseudomyxoma peritonei. The feasibility of surgery depends on the stage of pseudomyxoma peritonei at diagnosis. | ||
Revision as of 16:41, 14 January 2019
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei surgery On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei surgery |
|
Risk calculators and risk factors for Pseudomyxoma peritonei surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]Parminder Dhingra, M.D. [3]
Overview
Pseudomyxoma peritonei is rare clinical syndrome characterized by the accumulation of ascites mucins in peritoneum, mainly arises from the appendix. The mainstay of therapy in patients with pseudomyxoma peritonei is cytoreductive surgery combined with intraperitoneal chemo infusion.
Surgery
- Surgery is the mainstay of treatment for pseudomyxoma peritonei. The feasibility of surgery depends on the stage of pseudomyxoma peritonei at diagnosis.
- A more aggressive approach by Sugarbaker utilizes peritonectomy and visceral resections, called cytoreductive surgery (CRS), in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) that is featured by direct targeting of the microscopic disease, locoregional drug availability, minimal systemic exposure and improved drug penetration through hyperthermia.[1][2][1]
References
- ↑ 1.0 1.1 Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M (2009). "Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience". In Vivo. 23 (4): 639–44. PMID 19567401.
- ↑ Kitai T, Kawashima M, Yamanaka K, Ichijima K, Fujii H, Mashima S, Shimahara Y (September 2011). "Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals". Surg. Today. 41 (9): 1219–23. doi:10.1007/s00595-010-4495-6. PMID 21874418.